Home > Insider Trading > Filing (0001209191-18-053535)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724344	Entasis Therapeutics Holdings Inc.	ETTX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1365617	J Patrick Heron	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1655827	Frazier Life Sciences Viii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1698755	Fhm Life Sciences Viii, L.p.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No
1698823	Fhm Life Sciences Viii, L.l.c.	601 Union Street, Suite 3200 Seattle WA 98101	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-09-28	337,707	$0.00	337,707	No	4	C	Direct
Common Stock	Acquisiton	2018-09-28	251,487	$0.00	589,194	No	4	C	Direct
Common Stock	Acquisiton	2018-09-28	320,898	$0.00	974,066	No	4	C	Direct
Common Stock	Acquisiton	2018-09-28	375,887	$15.00	1,349,953	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-09-28	7,000,000	$0.00	337,707	$0.00
Common Stock	Series B-1 Tranche A Convertible Preferred Stock	Disposition	2018-09-28	5,212,833	$0.00	251,487	$0.00
Common Stock	Series B-1 Tranche B Convertible Preferred Stock	Disposition	2018-09-28	6,651,574	$0.00	320,898	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.
This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.